The FDA has granted traditional approval to Novartis’ Fabhalta (iptacopan) — the first complement inhibitor shown to significantly slow kidney function decline in adults with primary IgA nephropathy. Phase III APPLAUSE-IgAN data showed a 48% slower eGFR decline versus placebo over two years.
Novartis has announced a definitive agreement to acquire UK-based biotechnology firm Myricx Bio for USD 1.1 billion upfront plus USD 400 million in milestones, gaining a breakthrough NMTi payload platform targeting solid tumors.
Marking a major milestone, Novartis receives European Commission approval for Itvisma, introducing a fixed, one-time gene replacement therapy for a broad population of spinal muscular atrophy patients across Europe
Novartis announced impressive 144-week data for its groundbreaking STAMP inhibitor, showcasing widening superior molecular response rates and better tolerability compared to standard TKIs in newly diagnosed CML patients.
Novartis has announced groundbreaking results from the Phase III PSMAddition trial, revealing that Pluvicto significantly reduces the risk of PSA progression by 58% in patients with metastatic hormone-sensitive prostate cancer.
Novartis reports a resilient Q1 2026 with major gains in oncology and immunology, despite expected generic competition in the US market.
Novartis unveils over 20 abstracts at AAD 2026, highlighting Rhapsido’s (remibrutinib) early intervention in CSU and Cosentyx’s (secukinumab) sustained performance in complex skin diseases.
osentyx FDA approval marks first IL-17A inhibitor for pediatric patients 12+ with hidradenitis suppurativa. Discover how this breakthrough treatment transforms care for adolescents facing HS.
Swiss pharmaceutical giant Novartis AG (NYSE: NVS) has officially closed its acquisition of San Diego-based Avidity Biosciences, marking one of the most significant deals in the neuromuscular disease space in recent years. The transaction, originally announced on October 26, 2025, values Avidity at approximately $12 billion on a fully diluted basis, with an enterprise value of roughly $11 billion.
Novartis announced positive topline results from its pivotal Phase III RemIND trial of oral remibrutinib in chronic inducible urticaria (CIndU), demonstrating the potential to become [Read More…]
